Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

David’s Story

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

(Expert Access & Test Before Treat™)

This is just a brief note to tell you about the important impact you had on my treatment for CLL.

Last November, through the Expert Access program sponsored by the CLL Society, you were kind enough to review my medical records and chat with me about my condition and possible treatments. Although you said I appeared to be a decent candidate for FCR treatment, you pointed out that I had not had the IGVH test.

You said those results would be key to making a final decision about treatment. Our interview was especially timely because I was scheduled to begin FCR as prescribed by my local small-town oncologist.

After we chatted, I called my doctor’s office and requested the test. As it turned out, I was the first patient for whom he had ever prescribed this test. My IGVH status is un-mutated, so I began taking Imbruvica.

I believe you played a key early roll in my journey with CLL, and I wanted you to know about the crucial, positive impact you have had in my life.

CLL Society - Living With CLL

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.